title: [Memory B (CD5⁺ CD19⁺ CD27⁺) lymphocyte in patients with immune-related pancytopenia].
abstract: OBJECTIVE
  To detect memory B lymphocyte (Bm) in peripheral blood (PB) of immune-related pancytopenia (IRP).
  
  
  METHODS
  86 patients with IRP and 11 health volunteers were enrolled in this study. Bm (CD5⁺ CD19⁺ CD27⁺) and bone marrow mononucleated cell antibodies (BMMNC-Ab) were determined via fluorescence-activated cell sorting, and clinical outcomes of these patients were analyzed.
  
  
  RESULTS
  (1)43 initial patients achieved obvious remission in all 52 initial cases after conventional immunosuppression therapy. 16 relapsed patients with IRP received Rituximab (RTX) and 14 cases achieved obvious remission, among which 7 cases were refractory to conventional immunosuppression therapy, 5 cases exhibited obvious remission, and 2 cases did not respond. Other 18 relapsed cases received conventional immunosuppression therapy and 13 cases achieved obvious remission. (1)The level of Bm in PB in 52 initial patients with IRP was(1.81 ± 0.97)%, and no significant difference was observed between the initial patients and health volunteers (1.75 ± 0.55)% (P>0.05). The level of Bm in PB in 34 relapsed patients with IRP was obviously higher than that in the initial IRP patients and health volunteers (P<0.05). Significant difference was observed in the level of Bm in PB in 16 relapsed IRP patients between pre-therapy and post-therapy with RTX (P<0.05). No statistical difference was found between the remission and no-response groups in relapsed patients treated with RTX. RTX regimen produced more effective outcome than conventional immunosuppression therapy, which better eliminated Bm than the latter (P<0.05). Initial patients with IRP who relapsed within a two-year follow-up period had a lower level of Bm in PB compared with un-relapsed patients (P<0.05). Majority of BMMNC- Ab antibodies in relapsed patients were IgG (82.4%) and IgM (69.2%) autoantibodies in patients with initial IRP.
  
  
  CONCLUSIONS
  The level of Bm in PB was associated with relapsed patients with IRP. Bm did not respond to conventional immunosuppression therapy,but responded to RTX.
authors.affiliation: Department of Hematology, General Hospital,Tianjin Medical University,Tianjin 300052, China.
authors.forename: Yihao
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Hematology, General Hospital,Tianjin Medical University,Tianjin 300052, China.
authors.forename: Rong
authors.initials: R
authors.lastname: Fu
authors.affiliation: Department of Hematology, General Hospital,Tianjin Medical University,Tianjin 300052, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Liu
authors.affiliation: Department of Hematology, General Hospital,Tianjin Medical University,Tianjin 300052, China.
authors.forename: Honglei
authors.initials: H
authors.lastname: Wang
authors.affiliation: Department of Hematology, General Hospital,Tianjin Medical University,Tianjin 300052, China.
authors.forename: Tian
authors.initials: T
authors.lastname: Zhang
authors.affiliation: Department of Hematology, General Hospital,Tianjin Medical University,Tianjin 300052, China.
authors.forename: Shaoxue
authors.initials: S
authors.lastname: Ding
authors.affiliation: Department of Hematology, General Hospital,Tianjin Medical University,Tianjin 300052, China.
authors.forename: Jiangbo
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Department of Hematology, General Hospital,Tianjin Medical University,Tianjin 300052, China.
authors.forename: Shan
authors.initials: S
authors.lastname: Gao
authors.affiliation: Department of Hematology, General Hospital,Tianjin Medical University,Tianjin 300052, China.
authors.forename: Chunyan
authors.initials: C
authors.lastname: Liu
authors.affiliation: Department of Hematology, General Hospital,Tianjin Medical University,Tianjin 300052, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Hematology, General Hospital,Tianjin Medical University,Tianjin 300052, China.
authors.forename: Limin
authors.initials: L
authors.lastname: Xing
authors.affiliation: Department of Hematology, General Hospital,Tianjin Medical University,Tianjin 300052, China.
authors.forename: Huaquan
authors.initials: H
authors.lastname: Wang
authors.affiliation: Department of Hematology, General Hospital,Tianjin Medical University,Tianjin 300052, China.
authors.forename: Lijuan
authors.initials: L
authors.lastname: Li
authors.affiliation: Department of Hematology, General Hospital,Tianjin Medical University,Tianjin 300052, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Liu
authors.affiliation: Department of Hematology, General Hospital,Tianjin Medical University,Tianjin 300052, China.
authors.forename: Erbao
authors.initials: E
authors.lastname: Ruan
authors.affiliation: Department of Hematology, General Hospital,Tianjin Medical University,Tianjin 300052, China.
authors.forename: Jia
authors.initials: J
authors.lastname: Song
authors.affiliation: Department of Hematology, General Hospital,Tianjin Medical University,Tianjin 300052, China.
authors.forename: Yuhong
authors.initials: Y
authors.lastname: Wu
authors.affiliation: Department of Hematology, General Hospital,Tianjin Medical University,Tianjin 300052, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Guan
authors.affiliation: Department of Hematology, General Hospital,Tianjin Medical University,Tianjin 300052, China.
authors.forename: Wen
authors.initials: W
authors.lastname: Qu
authors.affiliation: Department of Hematology, General Hospital,Tianjin Medical University,Tianjin 300052, China.
authors.forename: Zonghong
authors.initials: Z
authors.lastname: Shao
mesh_terms: D000293:Adolescent; D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D016175:B-Lymphocyte Subsets / Q000276:immunology*; D005260:Female; D006801:Humans; D007156:Immunologic Memory; D007165:Immunosuppression Therapy; D008297:Male; D008875:Middle Aged; D010198:Pancytopenia / Q000276:immunology* / Q000628:therapy; D012008:Recurrence; D000069283:Rituximab; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab